NASDAQ:RAPP Rapport Therapeutics Q1 2026 Earnings Results & Report $28.99 -1.16 (-3.85%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$28.96 -0.02 (-0.09%) As of 10/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Rapport Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.42 versus the -$0.56 consensus estimate, while revenue of $20.00 million topped the $7.50 million estimate by $12.50 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 7, 2026TimeBefore Market OpensConference Call7:00 AM ET Rapport Therapeutics EPS ResultsActual EPS-$0.42Consensus EPS -$0.56Beat/MissBeat by +$0.14One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersRapport Therapeutics Revenue ResultsActual Revenue$20.00 millionExpected Revenue$7.50 millionBeat/MissBeat by +$12.50 millionYoY Revenue GrowthN/AUpcoming EarningsRapport Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rapport Therapeutics Q1 2026 Earnings FAQ Did Rapport Therapeutics beat earnings estimates for Q1 2026? Rapport Therapeutics (NASDAQ:RAPP) reported earnings of -$0.42 per share for Q1 2026, beating the consensus estimate of -$0.56. The report was announced on Thursday, May 7, 2026. What was Rapport Therapeutics' revenue for Q1 2026? Rapport Therapeutics reported revenue of $20.00 million for Q1 2026, against a consensus estimate of $7.50 million. When is Rapport Therapeutics' next earnings date? Rapport Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Rapport Therapeutics on the company's earnings history page. Rapport Therapeutics Earnings HeadlinesGuggenheim Upgrades Rapport Therapeutics (NASDAQ:RAPP) to "Strong-Buy"October 7, 2026 | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Stock: Insider Cheryl Gault Sells 10,000 SharesOctober 3, 2026 | americanbankingnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer. | Weiss Ratings (Ad)Show Me The Money: Rapport Stock Up Over 400% In 16 Months; Bipolar Mania Data NextSeptember 26, 2026 | rttnews.comAnalysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and The Estée Lauder Companies (EL)September 25, 2026 | theglobeandmail.comRapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating UpgradeSeptember 24, 2026 | seekingalpha.comSee More Rapport Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rapport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapport Therapeutics and other key companies, straight to your email. Email Address About Rapport TherapeuticsRapport Therapeutics (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system. Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy. The company is also advancing additional discovery and preclinical programs intended to address other nervous system conditions, with a focus on developing selective treatments that may offer improved efficacy and tolerability compared with less targeted approaches. Rapport Therapeutics was established to apply receptor-associated protein biology to drug discovery and is headquartered in Boston, Massachusetts. Its development efforts are directed primarily toward neurological and psychiatric diseases affecting patients in global markets. Information about the company’s leadership and broader commercial operations is limited because Rapport remains focused on clinical development rather than marketing approved products.View Rapport Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
